Treatment Patterns and Disease Burden of Juvenile Myasthenia Gravis in the United States
Patients with JMG escalated rapidly through the treatment hierarchy. Postpubertal-onset patients escalated more quickly to later-line treatments than prepubertal-onset patients. However, some patients continued to experience high HCRU, highlighting the need for new JMG treatments to provide rapid disease control. A limitation is that treatment escalation reasons were not evaluated.
Authors
- Frank Tennigkeit
- John F. Brandsema (ORCID: https://orcid.org/0000-0001-5945-3280)
- Nancy L. Kuntz (ORCID: https://orcid.org/0000-0003-2253-5156)
- Piotr Zaremba
- Sigrid Nilius
- Anna Scowcroft (ORCID: https://orcid.org/0000-0002-4727-9243)
- Jonathan B. Strober
- Olga Pilipczuk (ORCID: https://orcid.org/0000-0001-7078-2544)
- Thaïs Tarancón
- Jiachen Zhou (ORCID: https://orcid.org/0009-0006-2549-4686)
- Naveen S Chandra
Institutions
- Lurie Children's Hospital (US)
- Children's Hospital of Philadelphia (US)
- Urban College of Boston (US)
- University College Birmingham (GB)
- UCSF Benioff Children's Hospital (US)
- UCB Pharma (Germany) (DE)
Publication Details
- Journal
- Neurology
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1212/wnl.0000000000213736
- Citations
- 3
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 4.17